Autophagy is a multi-step process that is tightly regulated by various proteins. The team focused on a specific type of selective autophagy called LC3-associated phagocytosis (LAP), which is particularly important for the removal of damaged organelles and pathogens. They used a combination of advanced imaging techniques, biochemical assays, and genetic analyses to dissect the molecular events involved in LAP.
Their findings revealed the sequential recruitment and activation of key proteins that orchestrate LAP. The process starts with the recognition and targeting of damaged organelles by specific receptors. This leads to the formation of an isolation membrane around the damaged cargo, which then expands and matures into an autophagosome. The autophagosome ultimately fuses with lysosomes, resulting in the degradation and recycling of the engulfed material.
The researchers also discovered that SARS-CoV-2 infection can disrupt LAP by targeting key components of the LAP machinery. The virus hijacks the LAP pathway to facilitate its entry into host cells and evade immune detection. This subversion of LAP contributes to the pathogenicity of SARS-CoV-2 and could explain the observed cellular damage and dysregulation of immune responses in COVID-19 patients.
"Our comprehensive understanding of LAP provides new insights into cellular quality control mechanisms and suggests potential therapeutic avenues for treating diseases associated with autophagy dysfunction," says Professor Mizushima. "Furthermore, the discovery of SARS-CoV-2 interfering with LAP sheds light on the viral pathogenesis and could lead to the development of novel antiviral strategies."
This research, published in the journal Nature Cell Biology, highlights the importance of understanding the molecular basis of cellular processes in health and disease. By elucidating the detailed mechanisms of selective autophagy and its disruption by SARS-CoV-2, the team's findings pave the way for future therapeutic interventions targeting autophagy-related pathways.
